Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes

Journal of Nanoscience and Nanotechnology

Volumn 8, Issue 4, 2008, Pages 2102-2113

  Celia, Christian ^a   Calvagno, Maria Grazia ^a   Paolino, Donatella ^a   Bulotta, Stefania ^a   Ventura, Cinzia Anna ^b   Russo, Diego ^a   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cellular apoptosis; Gemcitabine; In Vitro anticancer cytotoxic effect; Intracellular drug uptake; Liposomes

Indexed keywords

(PEGYLATED) LIPOSOMES; APOPTOSIS INDUCTION; CARRIER (CO); CELL MORTALITY; CHEMOTHERAPEUTIC AGENTS; CONCENTRATION (COMPOSITION); CYTOTOXIC EFFECTS; DNA FRAGMENTATIONS; DOSE DEPENDENT; FUNCTION OF TIME; GEMCITABINE (GEM); IN-VITRO; INTRACELLULAR UPTAKE; LIPOSOMAL FORMULATION; LOADING CAPACITIES; MEAN SIZE; METHOXY-POLYETHYLENE GLYCOL (M-PEG SILANE); MOLAR RATIOS; PH GRADIENTS; PHOSPHOETHANOLAMINE; THYROID CARCINOMAS; UNILAMELLAR (UV) LIPOSOMES;

CELL CULTURE; CELL DEATH; CELLS; CHEMOTHERAPY; CIVIL AVIATION; DRUG DELIVERY; DRUG DOSAGE; ETHYLENE GLYCOL; GLYCOLS; NUCLEIC ACIDS; ORGANIC ACIDS; PHOSPHOLIPIDS; PHOTOACOUSTIC EFFECT; STABILIZERS (AGENTS); SUGAR (SUCROSE); ZETA POTENTIAL;

LIPOSOMES;

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG CARRIER; DRUG DERIVATIVE; GEMCITABINE; LIPOSOME; MACROGOL DERIVATIVE;

APOPTOSIS; ARTICLE; CHEMISTRY; DRUG EFFECT; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG CARRIERS; HUMANS; POLYETHYLENE GLYCOLS; THYROID NEOPLASMS; UNILAMELLAR LIPOSOMES;

EID: 44449096844     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2008.065     Document Type: Article

References (53)

1. M. A. Bookman, Int. J. Gynecol. Cancer 15, 12 (2005).
2. V. Heinemann, Oncology 64, 191 (2003).
3. B. Pauwels, A. E. Korst, F. Lardon, and J. B. Vermorken, Oncologist 10, 34 (2005).
4. S. Noble and K. L. Goa, Drugs 54, 447 (1997).
5. C. Manegold, Expert. Rev. Anticancer Ther. 4, 345 (2004).
6. P. Huang and W. Plunkett, Cancer Chemother. Pharmacol. 36, 181 (1995).
7. F. Barlesi, P. Villani, C. Doddoli, C. Gimenez, and J. P. Kleisbauer, Fundam. Clin. Pharmacol. 18, 85 (2004).
8. C. Kouroussis, D. Mavroudis, S. Kakolyris, A. Voloudaki, K. Kalbakis, J. Souglakos, S. Agelaki, K. Malas, V. Bozionelou, and V. Georgoulias, Lung Cancer 44, 363 (2004).
9. D. Santini, G. Tonini, A. Abbate, S. Di Cosimo, G. Gravante, B. Vincenzi, C. Campisi, G. Patti, and G. Di Sciascio, Ann. Oncol. 11, 479 (2000).
10. G. Cavallaro, M. Licciardi, G. Giammona, P. Caliceti, and S. Salmaso, Eur. J. Pharm. Biopharm. 58, 151 (2004).
11. G. Cavallaro, L. Maniscalco, M. Licciardi, and G. Giammona, Macromol. Biosci. 4, 1028 (2004).
12. H. S. Nalwa and T. J. Webster, Cancer Nanotechnology, American Scientific Publishers, Los Angeles (2007).
13. V. P. Torchilin. Crit. Rev. Ther. Drug Carrier Syst. 2. 65 (1985).
14. R. Moog. A. M. Burger. M. Brandi. J. Schiller. R. Schubert. C. Unger. H. 11. Fiebing. and V. Massing. Cancer Chemother Pharmacol. 49. 356 (2002).
15. D. C. Drummond. O. Meyer. K. Hong. D. B. Kirpotin and D. Papahadjopoulos. Pharmacol. Rev. 51, 691 (1999).
16. F. J. Martin, Clinical Pharmacology and Antitumor Efficacy of Doxil (Pegylated Liposomal Doxorubicin) in Medical Applications of Liposomes, Elsevier Science BV Press, Amsterdam (1998).
17. D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S. K. Huang, K. D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann, and F. J. Martin, Proc. Natl. Acad. Sci. USA 88, 11460 (1991).
18. L. D. Mayer, L. C. Tai, D. S. Ko, D. Masin, R. S. Ginsberg, P. R. Cullis, and M. B. Bally, Cancer Res. 49, 5922 (1989).
19. P. K. Working, M. S. Newman, S. K. Huang, E. Mayhew, J. Vaage, and D. D. Lasic, J. Liposome Res. 4, 667 (1994).
20. S. K. Hobbs, W L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. P. Jain, Proc. Natl. Acad. Sci. USA 95, 4607 (1998).
21. F. Castelli, A. Raudino, and M. Fresta, J. Colloid Interface Sci. 285. 110 (2005).
22. D. Paolino, M. Iannone, V. Cardile, M. Renis. G. Puglisi, D. Rotiroti, and M. Fresta, J. Pharm. Sci. 93, 1815 (2004).
23. M. D. Ringel, M. Greenberg, X. Chen, N. Hayre. K. Suzuki, D. Priebat, M. Saji, and K. D. Burman, Thyroid 10, 865 (2000).
24. M. Celano, M. G. Calvagno, S. Bulotta, D. Paolino, F. Arturi, D. Rotiroti, S. Filetti, M. Fresta, and D. Russo, BMC Cancer 4, 63 (2004).
25. K. B. Ain, Thyroid 8, 715 (1998).
26. K. Murayama, O. Ishida, S. Kosaoka, T. Takizawa, N. Utoguchi, A. Shinohara, M. Chiba, H. Kobayashi, M. Erighuchi, and H. Yanagie, J. Control. Rel. 98, 195 (2004).
27. E. Kedar, H. Gur, I. Babai, S. Samira, S. Even-Chen, and Y. Barenholz. J. Immunother. 23, 131 (2000).
28. T. Siegal, A. Horowitz, and A. Gabizon, J. Neurosurg. 83, 1029 (1995).
29. Y. Sadzuka, K. Kishi, S. Hirota, and T. Sonobe, J. Liposome Res. 13, 157 (2003).
30. Y. Sadzuka and S. Hirota, Cancer Lett. 131, 163 (1998).
31. A. Lawen, Bioessays 25, 888 (2003).
32. M. G. Calvagno, C. Celia, D. Paolino, D. Cosco, M. Iannone, F. Castelli, P. Doldo, and M. Fresta, Curr. Drug Deliv. 4, 89 (2007).
33. A. Gabizon, D. Goren, R. Cohen, and Y. Barenholz, J. Control. Rel. 53, 275 (1999).
34. A. Gabizon, H. Shmeeda, and Y. Barenholz, Clin. Pharmacokinet. 42, 419 (2003).
35. D. Paolino, G. Lucania, D. Mardente, F. Alhaique, and M. Fresta, J. Control. Rel. 106, 99 (2005).
36. J. F. Kerr, A. H. Wyllie, and A. R. Currie, British J. Cane. 26, 239 (1972).
37. Y. X. Zhang, S. B. Yu, J. P. OU-Yang, D. Xia, M. Wang, and J. R. Li, Acta Pharmacol. Sin. 26, 1365 (2005).
38. S. Vemuri and C. T. Rhodes, J. Pharm. Pharmacol. 46, 778 (1994).
39. A. S. Taggar, J. Alnajim, M. Anantha, A. Thomas, M. Webb, E. Ramsay, and M. B. Bally, J. Control. Rel. 114, 78 (2006).
40. I. V. Zhigaltsev, N. Maurer, Q. F. Akhong, R. Leone, E. Leng, J. Wang, S. C. Semple, and P. R. Cullis, J. Control. Rel. 104, 103 (2005).
41. A. Fritze, F. Hens, A. Kimpfier, R. Schubert, and R. Peschka-Suss, Biochim. Biophys. Acta 1758, 1633 (2006).
42. W. Liang, T. S. Levchenko, and V. P. Torchilin, J. Microencapsul. 21, 251 (2004).
43. P. J. Patty and B. J. Frisken, Biophys. J. 85, 996 (2003).
44. M. Fresta, M. Ricci, C. Rossi, P. M. Furneri, and G. Puglisi, J. Colloid Interface Sci. 226, 222 (2000).
45. A. Alexopoulos, D. Tryfonopoulos, M. V. Karamouzis, G. Gerasimidis, I. Karydas, K. Kandilis, J. Stavrakakis, H. Stavrinides, C. Georganta, A. Ardavanis, and G. Rigatos, Ann. Oncol. 15, 95 (2004).
46. M. L. Martelli, M. G. Miano, C. Battaglia, F. Trapasso, A. Stella, R. Iuliano, R. Visconti, J. A. Fagin, M. Santoro, and A. Fusco, Eur. J. Endocrinol. 143, 515 (2000).
47. B. Pauwels, A. E. Korst, G. G. Pattyn, H. A. Lambrechts, D. R. Van Bockstaele, K. Vermeulen, M. Lenjou, C. M. de Pooter, J. B. Vermorken, and F. Lardon, Int. J. Radiat. Oncol. Biol. Phys. 57, 1075 (2003).
48. C. Manegold, Expert Rev. Anticancer Ther.4, 345 (2004).
49. A. Matsuda and T. Sasaki, Cancer Sci. 95, 105 (2004).
50. J. L. Pasieka, Curr. Opin. Oncol. 15, 78 (2003).
51. L. Cartee, G. L. Kucera, and M. C. Willingham, Apoptosis 3, 439 (1998).
52. T. Lindahl, M. S. Satoh, G. G. Poirier, and A. Klungland, Trends Biochem. Sci. 20, 405 (1995).
53. M. Tewari, L. T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D. R. Beidler, G. G. Poirier, G. S. Salvesen, and V. M. Dixit, Cell 81, 801 (1995).